

**Anti-IL-1RAP / IL-1R3 Reference Antibody (nidanilimab)  
Recombinant Antibody  
Catalog # APR10161****Specification**

---

**Anti-IL-1RAP / IL-1R3 Reference Antibody (nidanilimab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">O9NPH3</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	144.48 KDa

**Anti-IL-1RAP / IL-1R3 Reference Antibody (nidanilimab) - Additional Information****Target/Specificity**

IL-1RAP / IL-1R3

**Endotoxin**

&lt; 0.001EU/ µg,determined by LAL method.

**Conjugation**

Unconjugated

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Anti-IL-1RAP / IL-1R3 Reference Antibody (nidanilimab) - Protein Information****Name** IL1RAP**Synonyms** C3orf13, IL1R3**Function**

Coreceptor for IL1RL2 in the IL-36 signaling system (By similarity). Coreceptor with IL1R1 in the IL-1 signaling system. Associates with IL1R1 bound to IL1B to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Recruits TOLLIP to the signaling complex. Does not bind to interleukin-1 alone; binding of IL1RN to IL1R1, prevents its association with IL1R1 to form a signaling complex. The cellular response is modulated through a non-signaling association with the membrane IL1R2 decoy receptor. Coreceptor for IL1RL1 in the IL-33 signaling system. Can bidirectionally induce pre- and postsynaptic differentiation of neurons by trans-synaptically binding to PTPRD (By similarity). May

play a role in IL1B-mediated costimulation of IFNG production from T-helper 1 (Th1) cells (Probable).

#### Cellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein [Isoform 3]: Secreted.

#### Tissue Location


Detected in liver, skin, placenta, thymus and lung. Isoform 4 is predominantly expressed in brain. Overexpressed on candidate chronic myeloid leukemia (CML) stem cells, hematopoietic stem cells and mononuclear cells of patients with acute myeloid leukemia (AML). Overexpressed in patients with chronic obstructive pulmonary disease (COPD). Expressed in T-helper 1 (Th1) and T-helper 2 (Th2) cell subsets (PubMed:10653850).

### Anti-IL-1RAP / IL-1R3 Reference Antibody (nidanimab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-IL-1RAP / IL-1R3 Reference Antibody (nidanimab) - Images



Anti-IL-1RAP / IL-1R3 Reference Antibody (nidanimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-1RAP / IL-1R3 Reference Antibody (nidanilimab) is more than 100% ,determined by SEC-HPLC.